- List
- By Topic
- On Map
- Search Details

Bortezomib | Recruiting, Not yet recruiting, Available Studies | "Multiple Myeloma"
Need help? See RSS Feeds
Choose a feed type:

Bortezomib | Recruiting, Not yet recruiting, Available Studies | "Multiple Myeloma" (75 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT01453088 | Recruiting | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
208 | All | 60 Years and older (Adult, Older Adult) | NCT01453088 | PRO# 1307 | June 24, 2010 | March 2020 | March 2020 | October 17, 2011 | August 7, 2018 |
|
|||
2 | NCT03110562 | Recruiting | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
364 | All | 18 Years and older (Adult, Older Adult) | NCT03110562 | KCP-330-023 | BOSTON | May 24, 2017 | June 2020 | June 2020 | April 12, 2017 | November 2, 2018 |
|
||
3 | NCT02703779 | Recruiting | Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Older Adult) | NCT02703779 | 2015-IIT-BMT-MM-AutoSCT | March 2016 | January 2019 | January 2019 | March 9, 2016 | May 2, 2018 |
|
|||
4 | NCT02718833 | Recruiting | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
46 | All | 18 Years and older (Adult, Older Adult) | NCT02718833 | 15-475 | June 2016 | September 2019 | September 2023 | March 24, 2016 | August 7, 2018 |
|
|||
5 | NCT03695744 | Not yet recruiting | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
63 | All | 18 Years to 85 Years (Adult, Older Adult) | NCT03695744 | AMN006 | October 2018 | March 2021 | October 2023 | October 4, 2018 | October 4, 2018 |
|
|||
6 | NCT02977494 | Recruiting | Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT02977494 | 2016-000433-51 | GMMG-DANTE | December 2016 | December 2020 | December 2022 | November 30, 2016 | March 27, 2017 |
|
||
7 | NCT03652064 | Recruiting | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
360 | All | 18 Years and older (Adult, Older Adult) | NCT03652064 | CR108529 2018-001545-13 54767414MMY3019 |
November 6, 2018 | March 29, 2024 | April 30, 2025 | August 29, 2018 | February 8, 2019 |
|
|||
8 | NCT01241708 | Recruiting | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
142 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT01241708 | Pro00001295 | (Mel/MelVel) | April 8, 2010 | February 2023 | February 2023 | November 16, 2010 | July 6, 2018 |
|
||
9 | NCT03314181 | Recruiting | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
90 | All | 18 Years and older (Adult, Older Adult) | NCT03314181 | M15-654 2017-002099-26 |
March 12, 2018 | November 4, 2020 | March 22, 2023 | October 19, 2017 | February 11, 2019 |
|
|||
10 | NCT03234972 | Recruiting | A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
210 | All | 18 Years and older (Adult, Older Adult) | NCT03234972 | CR104378 54767414MMY3009 |
November 30, 2017 | September 16, 2020 | August 31, 2022 | August 1, 2017 | December 13, 2018 |
|
|||
11 | NCT03217812 | Recruiting | A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
210 | All | 18 Years and older (Adult, Older Adult) | NCT03217812 | CR108340 54767414MMY3011 |
November 23, 2017 | January 17, 2020 | April 28, 2023 | July 14, 2017 | February 20, 2019 |
|
|||
12 | NCT03589222 | Recruiting | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
62 | All | 18 Years and older (Adult, Older Adult) | NCT03589222 | GEM- SELIBORDARA | July 15, 2018 | June 2019 | June 2022 | July 17, 2018 | July 27, 2018 |
|
|||
13 | NCT03729804 | Not yet recruiting | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
250 | All | 18 Years and older (Adult, Older Adult) | NCT03729804 | IRB18-1243 | (COBRA) | December 24, 2018 | December 24, 2021 | December 24, 2023 | November 5, 2018 | November 5, 2018 |
|
||
14 | NCT03544281 | Recruiting | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
90 | All | 18 Years and older (Adult, Older Adult) | NCT03544281 | 207497 | September 20, 2018 | June 29, 2020 | November 28, 2022 | June 1, 2018 | October 12, 2018 |
|
|||
15 | NCT03710603 | Recruiting | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Other / Industry |
|
|
690 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03710603 | EMN17/54767414MMY3014 | Perseus | December 14, 2018 | May 2029 | November 2029 | October 18, 2018 | January 17, 2019 |
|
||
16 | NCT03617731 | Recruiting | Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
662 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03617731 | GMMG HD7 | October 18, 2018 | May 2025 | December 2025 | August 6, 2018 | October 29, 2018 |
|
|||
17 | NCT03136653 | Recruiting | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03136653 | MP0250-CP201 2016-002771-10 |
May 23, 2017 | October 2019 | December 2019 | May 2, 2017 | February 18, 2019 |
|
|||
18 | NCT02654990 | Recruiting | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
240 | All | 18 Years and older (Adult, Older Adult) | NCT02654990 | CLBH589D2222 | PANORAMA_3 | April 27, 2016 | June 10, 2019 | December 15, 2022 | January 13, 2016 | February 20, 2019 |
|
||
19 | NCT02773030 | Recruiting | A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM) |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
154 | All | 18 Years and older (Adult, Older Adult) | NCT02773030 | CC-220-MM-001 | October 14, 2016 | March 16, 2021 | January 14, 2023 | May 16, 2016 | February 21, 2019 |
|
|||
20 | NCT03051841 | Recruiting | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
18 | All | 19 Years and older (Adult, Older Adult) | NCT03051841 | 133MM16010 | January 2017 | June 2019 | June 2021 | February 14, 2017 | July 26, 2018 |
|
|||
21 | NCT03210753 | Recruiting | Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma |
|
Observational |
|
Other |
|
|
400 | All | 20 Years and older (Adult, Older Adult) | NCT03210753 | 201610048RINA | December 1, 2016 | July 2020 | July 2020 | July 7, 2017 | July 13, 2017 |
|
|||||
22 | NCT03701321 | Recruiting | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
NIH |
|
|
282 | All | 18 Years and older (Adult, Older Adult) | NCT03701321 | NCI-2018-02131 EAA172 U10CA180820 |
January 25, 2019 | October 31, 2023 | October 31, 2023 | October 10, 2018 | February 11, 2019 |
|
|||
23 | NCT03481556 | Recruiting | Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
80 | All | 18 Years and older (Adult, Older Adult) | NCT03481556 | OP-104 | ANCHOR | April 16, 2018 | December 31, 2019 | December 31, 2021 | March 29, 2018 | June 4, 2018 |
|
||
24 | NCT03763162 | Not yet recruiting | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry / NIH |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT03763162 | 2018-0512 NCI-2018-02830 P30CA016672 |
April 30, 2019 | December 31, 2023 | December 31, 2023 | December 4, 2018 | February 19, 2019 |
|
|||
25 | NCT02513186 | Recruiting | Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
44 | All | 18 Years and older (Adult, Older Adult) | NCT02513186 | TCD13983 2014-001251-23 U1111-1154-6102 |
CyBorDSAR | September 30, 2015 | October 2022 | October 2022 | July 31, 2015 | January 31, 2019 |
|
||
26 | NCT01863550 | Recruiting | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Other / NIH |
|
|
1080 | All | 18 Years and older (Adult, Older Adult) | NCT01863550 | E1A11 NCI-2012-02608 ECOG-E1A11 s17-00040 U10CA180820 U10CA021115 U24CA196172 |
December 2, 2013 | November 1, 2023 | May 29, 2013 | August 22, 2018 |
|
||||
27 | NCT03173092 | Recruiting | An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) |
|
|
Interventional |
Phase 4 |
|
Industry |
|
|
160 | All | 18 Years and older (Adult, Older Adult) | NCT03173092 | C16038 U1111-1192-7696 |
September 20, 2017 | November 30, 2023 | November 30, 2023 | June 1, 2017 | February 6, 2019 |
|
|||
28 | NCT03759093 | Not yet recruiting | CURATE.AI Optimized Modulation for Multiple Myeloma |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
20 | All | 21 Years to 99 Years (Adult, Older Adult) | NCT03759093 | 2015/00280 | January 1, 2019 | January 1, 2021 | January 1, 2021 | November 29, 2018 | November 29, 2018 |
|
|||
29 | NCT02086942 | Recruiting | Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma. |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
94 | All | 18 Years and older (Adult, Older Adult) | NCT02086942 | NAB20130806 | August 2013 | August 2017 | August 2017 | March 13, 2014 | August 29, 2017 |
|
|||
30 | NCT02568943 | Available | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma |
|
|
Expanded Access |
|
Industry | All | 18 Years and older (Adult, Older Adult) | NCT02568943 | CLBH589D2001X | October 6, 2015 | October 11, 2018 |
|
||||||||||
31 | NCT03319667 | Recruiting | Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
440 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03319667 | EFC12522 2017-002238-21 U1111-1194-2121 |
IMROZ | December 7, 2017 | December 2022 | January 2025 | October 24, 2017 | February 18, 2019 |
|
||
32 | NCT01415882 | Recruiting | Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib |
|
|
Interventional |
Phase 2 |
|
Other / NIH / Industry |
|
|
144 | All | 18 Years and older (Adult, Older Adult) | NCT01415882 | MC1181 NCI-2011-02303 11-001516 00 Mod11-001516-50 P30CA015083 |
February 4, 2016 | April 1, 2019 | April 1, 2019 | August 12, 2011 | January 21, 2019 |
|
|||
33 | NCT03641456 | Not yet recruiting | VRD as Induction Followed by IR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
50 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03641456 | MM-2018 | January 10, 2019 | September 30, 2020 | September 30, 2022 | August 22, 2018 | January 21, 2019 |
|
|||
34 | NCT03344328 | Not yet recruiting | Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. |
|
|
Observational |
|
Other |
|
|
360 | All | 18 Years and older (Adult, Older Adult) | NCT03344328 | CHU-359 | PREVIB | January 1, 2018 | June 1, 2018 | September 30, 2018 | November 17, 2017 | November 21, 2017 |
|
|||
35 | NCT03829371 | Recruiting New |
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA |
|
|
Interventional |
Phase 4 |
|
Other |
|
|
350 | All | 65 Years and older (Older Adult) | NCT03829371 | Real MM | January 3, 2019 | January 3, 2023 | January 3, 2023 | February 4, 2019 | February 11, 2019 |
|
|||
36 | NCT02424851 | Recruiting | Optimising Renal Outcome in Myeloma Renal Failure |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
120 | All | 18 Years and older (Adult, Older Adult) | NCT02424851 | 26866138-MMY2070 2012-003947-31 |
OPTIMAL | November 2014 | January 2019 | June 2019 | April 23, 2015 | May 11, 2018 |
|
||
37 | NCT02343042 | Recruiting | Selinexor and Backbone Treatments of Multiple Myeloma Patients |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
321 | All | 18 Years and older (Adult, Older Adult) | NCT02343042 | KCP-330-017 | STOMP | October 2015 | March 2019 | April 2019 | January 21, 2015 | October 16, 2018 |
|
||
38 | NCT01250808 | Available | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy |
|
|
Expanded Access |
|
Other | All | 18 Years and older (Adult, Older Adult) | NCT01250808 | 2008ZX09312-026 | December 1, 2010 | December 1, 2010 |
|
||||||||||
39 | NCT03742297 | Recruiting | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
300 | All | 65 Years to 80 Years (Older Adult) | NCT03742297 | GEM2017FIT | October 22, 2018 | October 22, 2020 | October 22, 2021 | November 15, 2018 | November 21, 2018 |
|
|||
40 | NCT03188172 | Recruiting | MUK Nine b: OPTIMUM Treatment Protocol |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
95 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT03188172 | HM16/235 | MUKnineb | September 28, 2017 | October 1, 2020 | December 31, 2021 | June 15, 2017 | September 13, 2018 |
|
||
41 | NCT03242460 | Recruiting | The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
55 | All | 18 Years and older (Adult, Older Adult) | NCT03242460 | PORYOU | PORYOU | May 12, 2015 | December 31, 2018 | December 31, 2019 | August 8, 2017 | August 8, 2017 |
|
||
42 | NCT03829020 | Not yet recruiting New |
Metformin and Nelfinavir in Treating Patients With Relapsed and/or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / NIH |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT03829020 | MC1811 NCI-2019-00466 P30CA015083 |
March 1, 2019 | August 21, 2021 | August 21, 2021 | February 4, 2019 | February 4, 2019 |
|
|||
43 | NCT02188368 | Recruiting | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
45 | All | 18 Years and older (Adult, Older Adult) | NCT02188368 | PO-CL-MM-PI-003854 | August 2014 | December 2018 | December 2018 | July 11, 2014 | October 5, 2018 |
|
|||
44 | NCT02981199 | Recruiting | Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
80 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02981199 | MM-MSCT-001 | January 2016 | December 2018 | December 2019 | December 5, 2016 | December 16, 2016 |
|
|||
45 | NCT03416374 | Recruiting | A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy |
|
|
Interventional |
Phase 4 |
|
Industry |
|
|
47 | All | 20 Years and older (Adult, Older Adult) | NCT03416374 | C16043 U1111-1207-0061 JapicCTI-183839 |
March 13, 2018 | February 28, 2020 | May 31, 2021 | January 31, 2018 | July 23, 2018 |
|
|||
46 | NCT02461888 | Recruiting | Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
250 | All | 18 Years and older (Adult, Older Adult) | NCT02461888 | HM13/10993 | MUKEight | December 2015 | May 2018 | May 2019 | June 3, 2015 | November 17, 2016 |
|
||
47 | NCT02164955 | Recruiting | A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma. |
|
|
Observational |
|
Industry |
|
|
750 | All | 18 Years and older (Adult, Older Adult) | NCT02164955 | CC-4047-MM-015 | June 26, 2014 | August 31, 2022 | August 31, 2022 | June 17, 2014 | December 7, 2018 |
|
||||
48 | NCT03393273 | Not yet recruiting | Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
35 | All | 66 Years and older (Older Adult) | NCT03393273 | P170103 2017-001446-10 |
IFM2016-03 | May 2018 | May 2023 | May 2023 | January 8, 2018 | May 15, 2018 | |||
49 | NCT03651128 | Not yet recruiting | Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
381 | All | 18 Years and older (Adult, Older Adult) | NCT03651128 | BB2121-MM-003 U1111-1217-9988 2018-001023-38 |
KarMMa-3 | November 30, 2018 | June 9, 2025 | June 9, 2025 | August 29, 2018 | October 25, 2018 |
|
||
50 | NCT03004287 | Recruiting | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
50 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03004287 | 206241 | July 1, 2017 | January 2021 | January 2021 | December 28, 2016 | July 16, 2018 |
|
|||
51 | NCT03733691 | Not yet recruiting | Phase 2 Maintenance Trial: Ixazomib Compared to Ixazomib-Lenalidomide Combination as Maintenance Therapy for Frontline Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
52 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT03733691 | X16108 | December 20, 2018 | December 20, 2023 | February 20, 2024 | November 7, 2018 | November 9, 2018 | ||||
52 | NCT03140943 | Recruiting | Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
100 | All | 21 Years to 99 Years (Adult, Older Adult) | NCT03140943 | AMN002 | September 13, 2017 | June 1, 2019 | June 1, 2022 | May 4, 2017 | November 6, 2017 |
|
|||
53 | NCT00720785 | Recruiting | Natural Killer Cells and Bortezomib to Treat Cancer |
|
|
Interventional |
Phase 1 |
|
NIH |
|
|
61 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT00720785 | 080186 08-H-0186 |
August 1, 2008 | January 1, 2020 | January 1, 2020 | July 23, 2008 | December 18, 2018 |
|
|||
54 | NCT03477643 | Recruiting | Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) |
|
Observational |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Older Adult) | NCT03477643 | GEM-POMCIDEX | April 27, 2018 | March 13, 2019 | December 13, 2019 | March 26, 2018 | February 1, 2019 |
|
|||||
55 | NCT02412228 | Recruiting | BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT02412228 | 299 | August 2015 | May 2019 | September 2019 | April 9, 2015 | November 30, 2018 |
|
|||
56 | NCT02439476 | Recruiting | Non-interventional Study on Salvage Auto in Relapsed Myeloma |
|
Observational |
|
Other |
|
|
30 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT02439476 | IFM-2015-03 | IFM-2015-03 | August 8, 2016 | June 2019 | June 2020 | May 8, 2015 | January 9, 2019 |
|
||||
57 | NCT03143049 | Recruiting | Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma |
|
|
Interventional |
Phase 3 |
|
Other / Industry |
|
|
120 | All | 21 Years to 99 Years (Adult, Older Adult) | NCT03143049 | AMN003 | September 13, 2017 | June 1, 2018 | June 1, 2022 | May 8, 2017 | November 6, 2017 |
|
|||
58 | NCT02555839 | Recruiting | Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice |
|
|
Observational |
|
Industry |
|
|
70 | All | 18 Years and older (Adult, Older Adult) | NCT02555839 | CC-4047-MM-017 | March 1, 2015 | September 30, 2019 | September 30, 2019 | September 22, 2015 | November 14, 2018 |
|
||||
59 | NCT03795597 | Not yet recruiting | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT03795597 | 209274 | BuMelCarAuto | February 1, 2019 | November 1, 2021 | November 1, 2023 | January 8, 2019 | January 8, 2019 | |||
60 | NCT03288974 | Recruiting | Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea |
|
|
Observational |
|
Industry |
|
|
600 | All | 19 Years and older (Adult, Older Adult) | NCT03288974 | NIPMS-POM-KR-001 U1111-1201-1712 |
Pomalyst PMS | December 28, 2017 | June 8, 2023 | June 8, 2023 | September 20, 2017 | May 21, 2018 |
|
|||
61 | NCT03601624 | Recruiting | Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
18 | All | 18 Years and older (Adult, Older Adult) | NCT03601624 | ISSSTE-POM-CY-MM-2018 | MM-POM-2018 | September 1, 2018 | December 31, 2018 | July 30, 2020 | July 26, 2018 | November 14, 2018 |
|
||
62 | NCT03030261 | Recruiting | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
40 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03030261 | 201701084 CA204-225 PO-CL-MM-PI-008341 |
November 22, 2017 | May 31, 2021 | February 28, 2026 | January 24, 2017 | January 21, 2019 |
|
|||
63 | NCT03104270 | Recruiting | Combination Study for High Risk Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03104270 | CA204-187 | March 13, 2017 | February 2020 | May 2020 | April 7, 2017 | January 8, 2019 |
|
|||
64 | NCT03515915 | Recruiting | Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment |
|
Observational |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT03515915 | UF9760 | April 23, 2018 | December 31, 2018 | December 31, 2019 | May 4, 2018 | May 11, 2018 |
|
|||||
65 | NCT03836014 | Not yet recruiting New |
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
434 | All | 18 Years and older (Adult, Older Adult) | NCT03836014 | D20180138 2016-002129-12 |
CONFIRM | March 2019 | March 2023 | March 2025 | February 11, 2019 | February 11, 2019 |
|
||
66 | NCT03361306 | Recruiting | LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03361306 | LCI-HEM-MYE-CRD-002 | December 15, 2017 | December 31, 2020 | December 31, 2020 | December 4, 2017 | November 16, 2018 |
|
|||
67 | NCT03440411 | Recruiting | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
260 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03440411 | PO-CL-MM-PI-003887 | PO-3887 | February 18, 2016 | February 18, 2021 | February 18, 2023 | February 21, 2018 | February 21, 2018 |
|
||
68 | NCT00871013 | Recruiting | UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant) |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
160 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT00871013 | 108053 | March 2009 | December 2020 | December 2020 | March 30, 2009 | April 26, 2018 |
|
|||
69 | NCT03143036 | Recruiting | Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
100 | All | 21 Years to 99 Years (Adult, Older Adult) | NCT03143036 | AMN004 | May 1, 2018 | July 1, 2019 | July 1, 2022 | May 8, 2017 | June 7, 2018 |
|
|||
70 | NCT03670173 | Not yet recruiting | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT03670173 | STPH-MM001 | October 1, 2018 | January 31, 2020 | September 30, 2020 | September 13, 2018 | September 13, 2018 | ||||
71 | NCT03607643 | Not yet recruiting | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
160 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03607643 | Olympian | January 15, 2019 | June 30, 2020 | December 15, 2020 | July 31, 2018 | July 31, 2018 |
|
|||
72 | NCT02577783 | Recruiting | PDD vs PAD to Treat Initially Diagnosed MM |
|
|
Interventional |
Phase 4 |
|
Other |
|
|
64 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT02577783 | SZ5202 | October 2015 | October 2019 | December 2019 | October 16, 2015 | October 16, 2015 |
|
|||
73 | NCT03530683 | Recruiting | A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
156 | All | 18 Years and older (Adult, Older Adult) | NCT03530683 | TTI-622-01 | TTI-622-01 | May 1, 2018 | August 20, 2020 | April 22, 2021 | May 21, 2018 | December 24, 2018 |
|
||
74 | NCT00734877 | Recruiting | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma |
|
|
Interventional |
Phase 3 |
|
Other / Industry |
|
|
400 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT00734877 | 103668 | TT4B | July 2008 | September 2020 | September 2020 | August 14, 2008 | October 16, 2018 |
|
||
75 | NCT03490084 | Not yet recruiting | Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma |
|
|
Observational |
|
Other |
|
|
300 | All | 65 Years and older (Older Adult) | NCT03490084 | P_PREPS 16-596 | PAMM-HAD1 | January 2019 | September 2021 | September 2021 | April 6, 2018 | October 16, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.